Pender Fund Capital Management Ltd. Inozyme Pharma, Inc. Transaction History
Pender Fund Capital Management Ltd.
- $154 Million
- Q2 2025
A detailed history of Pender Fund Capital Management Ltd. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Pender Fund Capital Management Ltd. holds 90,700 shares of INZY stock, worth $362,800. This represents 0.24% of its overall portfolio holdings.
Number of Shares
90,700Holding current value
$362,800% of portfolio
0.24%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
87Shares Held
51.9MCall Options Held
162KPut Options Held
0-
Beryl Capital Management LLC Redondo Beach, CA6.32MShares$25.3 Million3.83% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million16.98% of portfolio
-
Glazer Capital, LLC New York, NY4.33MShares$17.3 Million0.62% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million1.16% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...